Rank #1273KOD

Kodiak Sciences Inc

$26.66

8.48% (Daily)

Market Cap

$1.63B

Revenue

$N/A

Rank by MCap

#1273

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Victor Perlroth M.D.

Headquarters

Palo Alto, CA

Employees

123

About Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degener...